Skip to content

reduce vomiting associated ketamine

Effect of ondansetron on the incidence of ketamine associated vomiting

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180129038549N1
Enrollment
180
Registered
2018-01-31
Start date
2018-01-30
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laceration repair.

Interventions

Intervention 1: Intervention group: Administering the Ondansetron 1.5 mg/kg (Exir) + Ketamine in sedation. Intervention 2: Control group: Administering the Placebo( normal saline).
Treatment - Drugs
Placebo
Intervention group: Administering the Ondansetron 1.5 mg/kg (Exir) + Ketamine in sedation
Control group: Administering the Placebo( normal saline)

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 1 Years

Inclusion criteria

Inclusion criteria: children aged 1-10 years who received IV or IM ketamine for laceration repair

Exclusion criteria

Exclusion criteria: parents unwilling to provide informed consent history of psychosis , hypertension, intracranial hemorrhage Nothing-by-mouth (NPO) time less than 3 hours use of anti-emetic drugs before treatment

Design outcomes

Primary

MeasureTime frame
The incidence of nausea and vomiting in the ED. Timepoint: In the emergency department. Method of measurement: The incidence of nausea and vomiting.

Secondary

MeasureTime frame
Other complications of Ketamine and Ondansetron. Timepoint: In the emergency department. Method of measurement: The incidence.;Emergency department length of stay. Timepoint: Before discharge. Method of measurement: Time(minute).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarhad Heydari

Esfahan University of Medical Sciences

drfarhadheydari@gmail.com+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026